Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle
Open Access

Novel Small Molecule Fibroblast Growth Factor 23 Inhibitors Increase Serum Phosphate and Improve Skeletal Abnormalities in Hyp Mice

Zhousheng Xiao, Jiawang Liu, Shih-Hsien Liu, Loukas Petridis, Chun Cai, Li Cao, Guangwei Wang, Ai Lin Chin, Jacob W. Cleveland, Munachi O. Ikedionwu, Jesse D. Carrick, Jeremy C. Smith and Leigh Darryl Quarles
Molecular Pharmacology June 2022, 101 (6) 408-421; DOI: https://doi.org/10.1124/molpharm.121.000471
Zhousheng Xiao
Department of Medicine, College of Medicine (Z.X., C.C., L.C., G.W.W., L.D.Q.) and Department of Pharmaceutical Sciences, College of Pharmacy (J.L.), University of Tennessee Health Science Center, Memphis, Tennessee; University of Tennessee (UT)/Oak Ridge National Laboratory (ORNL) Center for Molecular Biophysics, Oak Ridge National Laboratory, Oak Ridge, Tennessee (S.H.L., L.P., J.C.S.); Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, Tennessee (L.P., J.C.S.); and Department of Chemistry, Tennessee Technological University, Cookeville, Tennessee (A.L.C., J.W.C., M.O.I., J.D.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiawang Liu
Department of Medicine, College of Medicine (Z.X., C.C., L.C., G.W.W., L.D.Q.) and Department of Pharmaceutical Sciences, College of Pharmacy (J.L.), University of Tennessee Health Science Center, Memphis, Tennessee; University of Tennessee (UT)/Oak Ridge National Laboratory (ORNL) Center for Molecular Biophysics, Oak Ridge National Laboratory, Oak Ridge, Tennessee (S.H.L., L.P., J.C.S.); Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, Tennessee (L.P., J.C.S.); and Department of Chemistry, Tennessee Technological University, Cookeville, Tennessee (A.L.C., J.W.C., M.O.I., J.D.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shih-Hsien Liu
Department of Medicine, College of Medicine (Z.X., C.C., L.C., G.W.W., L.D.Q.) and Department of Pharmaceutical Sciences, College of Pharmacy (J.L.), University of Tennessee Health Science Center, Memphis, Tennessee; University of Tennessee (UT)/Oak Ridge National Laboratory (ORNL) Center for Molecular Biophysics, Oak Ridge National Laboratory, Oak Ridge, Tennessee (S.H.L., L.P., J.C.S.); Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, Tennessee (L.P., J.C.S.); and Department of Chemistry, Tennessee Technological University, Cookeville, Tennessee (A.L.C., J.W.C., M.O.I., J.D.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Loukas Petridis
Department of Medicine, College of Medicine (Z.X., C.C., L.C., G.W.W., L.D.Q.) and Department of Pharmaceutical Sciences, College of Pharmacy (J.L.), University of Tennessee Health Science Center, Memphis, Tennessee; University of Tennessee (UT)/Oak Ridge National Laboratory (ORNL) Center for Molecular Biophysics, Oak Ridge National Laboratory, Oak Ridge, Tennessee (S.H.L., L.P., J.C.S.); Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, Tennessee (L.P., J.C.S.); and Department of Chemistry, Tennessee Technological University, Cookeville, Tennessee (A.L.C., J.W.C., M.O.I., J.D.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chun Cai
Department of Medicine, College of Medicine (Z.X., C.C., L.C., G.W.W., L.D.Q.) and Department of Pharmaceutical Sciences, College of Pharmacy (J.L.), University of Tennessee Health Science Center, Memphis, Tennessee; University of Tennessee (UT)/Oak Ridge National Laboratory (ORNL) Center for Molecular Biophysics, Oak Ridge National Laboratory, Oak Ridge, Tennessee (S.H.L., L.P., J.C.S.); Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, Tennessee (L.P., J.C.S.); and Department of Chemistry, Tennessee Technological University, Cookeville, Tennessee (A.L.C., J.W.C., M.O.I., J.D.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li Cao
Department of Medicine, College of Medicine (Z.X., C.C., L.C., G.W.W., L.D.Q.) and Department of Pharmaceutical Sciences, College of Pharmacy (J.L.), University of Tennessee Health Science Center, Memphis, Tennessee; University of Tennessee (UT)/Oak Ridge National Laboratory (ORNL) Center for Molecular Biophysics, Oak Ridge National Laboratory, Oak Ridge, Tennessee (S.H.L., L.P., J.C.S.); Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, Tennessee (L.P., J.C.S.); and Department of Chemistry, Tennessee Technological University, Cookeville, Tennessee (A.L.C., J.W.C., M.O.I., J.D.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guangwei Wang
Department of Medicine, College of Medicine (Z.X., C.C., L.C., G.W.W., L.D.Q.) and Department of Pharmaceutical Sciences, College of Pharmacy (J.L.), University of Tennessee Health Science Center, Memphis, Tennessee; University of Tennessee (UT)/Oak Ridge National Laboratory (ORNL) Center for Molecular Biophysics, Oak Ridge National Laboratory, Oak Ridge, Tennessee (S.H.L., L.P., J.C.S.); Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, Tennessee (L.P., J.C.S.); and Department of Chemistry, Tennessee Technological University, Cookeville, Tennessee (A.L.C., J.W.C., M.O.I., J.D.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ai Lin Chin
Department of Medicine, College of Medicine (Z.X., C.C., L.C., G.W.W., L.D.Q.) and Department of Pharmaceutical Sciences, College of Pharmacy (J.L.), University of Tennessee Health Science Center, Memphis, Tennessee; University of Tennessee (UT)/Oak Ridge National Laboratory (ORNL) Center for Molecular Biophysics, Oak Ridge National Laboratory, Oak Ridge, Tennessee (S.H.L., L.P., J.C.S.); Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, Tennessee (L.P., J.C.S.); and Department of Chemistry, Tennessee Technological University, Cookeville, Tennessee (A.L.C., J.W.C., M.O.I., J.D.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacob W. Cleveland
Department of Medicine, College of Medicine (Z.X., C.C., L.C., G.W.W., L.D.Q.) and Department of Pharmaceutical Sciences, College of Pharmacy (J.L.), University of Tennessee Health Science Center, Memphis, Tennessee; University of Tennessee (UT)/Oak Ridge National Laboratory (ORNL) Center for Molecular Biophysics, Oak Ridge National Laboratory, Oak Ridge, Tennessee (S.H.L., L.P., J.C.S.); Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, Tennessee (L.P., J.C.S.); and Department of Chemistry, Tennessee Technological University, Cookeville, Tennessee (A.L.C., J.W.C., M.O.I., J.D.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Munachi O. Ikedionwu
Department of Medicine, College of Medicine (Z.X., C.C., L.C., G.W.W., L.D.Q.) and Department of Pharmaceutical Sciences, College of Pharmacy (J.L.), University of Tennessee Health Science Center, Memphis, Tennessee; University of Tennessee (UT)/Oak Ridge National Laboratory (ORNL) Center for Molecular Biophysics, Oak Ridge National Laboratory, Oak Ridge, Tennessee (S.H.L., L.P., J.C.S.); Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, Tennessee (L.P., J.C.S.); and Department of Chemistry, Tennessee Technological University, Cookeville, Tennessee (A.L.C., J.W.C., M.O.I., J.D.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jesse D. Carrick
Department of Medicine, College of Medicine (Z.X., C.C., L.C., G.W.W., L.D.Q.) and Department of Pharmaceutical Sciences, College of Pharmacy (J.L.), University of Tennessee Health Science Center, Memphis, Tennessee; University of Tennessee (UT)/Oak Ridge National Laboratory (ORNL) Center for Molecular Biophysics, Oak Ridge National Laboratory, Oak Ridge, Tennessee (S.H.L., L.P., J.C.S.); Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, Tennessee (L.P., J.C.S.); and Department of Chemistry, Tennessee Technological University, Cookeville, Tennessee (A.L.C., J.W.C., M.O.I., J.D.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremy C. Smith
Department of Medicine, College of Medicine (Z.X., C.C., L.C., G.W.W., L.D.Q.) and Department of Pharmaceutical Sciences, College of Pharmacy (J.L.), University of Tennessee Health Science Center, Memphis, Tennessee; University of Tennessee (UT)/Oak Ridge National Laboratory (ORNL) Center for Molecular Biophysics, Oak Ridge National Laboratory, Oak Ridge, Tennessee (S.H.L., L.P., J.C.S.); Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, Tennessee (L.P., J.C.S.); and Department of Chemistry, Tennessee Technological University, Cookeville, Tennessee (A.L.C., J.W.C., M.O.I., J.D.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leigh Darryl Quarles
Department of Medicine, College of Medicine (Z.X., C.C., L.C., G.W.W., L.D.Q.) and Department of Pharmaceutical Sciences, College of Pharmacy (J.L.), University of Tennessee Health Science Center, Memphis, Tennessee; University of Tennessee (UT)/Oak Ridge National Laboratory (ORNL) Center for Molecular Biophysics, Oak Ridge National Laboratory, Oak Ridge, Tennessee (S.H.L., L.P., J.C.S.); Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, Tennessee (L.P., J.C.S.); and Department of Chemistry, Tennessee Technological University, Cookeville, Tennessee (A.L.C., J.W.C., M.O.I., J.D.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Structure, in vitro efficacy, and metabolic stability of ZINC13407541 (A) and its analogs 8n (B) and 13a (C). IC50 values were extracted from three independent concentration-response experiments examining the compound-dependent inhibition of FGF23-induced ERK reporter activities in HEK293T cells expressing human α-KL after application of ZINC13407541 (n = 3 cells) and its analogs 8n (n = 3 cells) and 13a (n = 3 cells). Maximum percent inhibition values were calculated from the plateaus in inhibition at the highest inhibitor concentration (n = 3 cells for each compound). Metabolic stabilities were expressed as the half-life of the parent compound remaining after an incubation with human liver microsomes (n = 3 liver microsomes for each compound).

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    The computationally predicted interaction of ZINC13407541 and its two analogs, 13a and 8n, with Gln156, the potential binding site, in the N-terminal domain of FGF23 (PDB code: 5W21) shown in (A) 3D structure; (B–D) two-dimensional residue-contacting map for ZINC13407541, 13a, and 8n, respectively. Hydrogen bonds are shown in red dash lines with donor-acceptor distances in Å. Hydrophobic interactions are shown in gray. The corresponding estimated free energies of binding (ΔG) for the three poses are shown in Table 2.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Effects of ZINC13407541 and its analogs on CFP-FGF23WT or CFP-FGF23Q156A induced BiFC-based FRET ratio and ERK reporter activities. (A) Diagrams of fusion constructs for human CFP-FGF23WT, CFP-FGF23Q156A, α-KL-VN155, and FGFR1-VC155. (B) BiFC-based YFP/CFP ratio (n = 3 cells). (C) ERK reporter activities (n = 3 cells). (D) Computational model of FGF23 antagonist that targets FGF23/FGFR1/α-Klotho complex. Data are expressed as the mean ± S.D. from three independent experiments. *, **, and *** indicate statistically significant difference from vehicle control group. P values were determined by one-way ANOVA with Tukey’s multiple-comparisons test.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Time- and dose-dependent effects of ZINC13407541 on mineral ion homeostasis and FGF23 levels in Hyp mice. In left panels (A), (C), and (E), time-course assessments of serum phosphate, calcium, and FGF23 levels in Hyp mice that were given a single i.p. injection of ZINC13407541 (100mg/kg) during 24 hours. In right panels (B), (D), and (F), dose-response studies of serum phosphate, calcium, and FGF23 levels in Hyp mice that were given a single i.p. injection of ZINC13407541 (50, 100, and 200 mg/kg) after 4 hours. Data are expressed as the mean ± S.D. from serum samples of individual mice (n = 5). *, **, and *** indicate statistically significant difference from vehicle control group. P values were determined by 1-way ANOVA with Dunnett's test.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Time- and dose-dependent effects of 13a on mineral ion homeostasis and FGF23 levels in Hyp mice. In left panels (A), (C), and (E), time-course assessments of serum phosphate, calcium, and FGF23 levels in Hyp mice that were given a single i.p. injection of 13a (100mg/kg) during 24 hours. In right panels (B), (D), and (F), dose-response studies of serum phosphate, calcium, and FGF23 levels in Hyp mice that were given a single i.p. injection of 13a (10, 50, and 100 mg/kg) after 4 hours. Data are expressed as the mean ± S.D. from serum samples of individual mice (n = 5). *, **, and *** indicate statistically significant difference from vehicle control group. P values were determined by one-way ANOVA with Dunnett's test.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Short-term effects of ZINC13407541, 8n, and 13a on mineral ion homeostasis and FGF23 levels in Hyp mice. (A–C) Serum phosphate. (D–F) Serum calcium. (G–I) Serum FGF23. Data are expressed as the mean ± S.D. from serum samples of individual mice (n = 5). *, **, and *** indicate statistically significant difference from vehicle control group. P values were determined by two-way ANOVA with Bonferroni post hoc test.

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    Long-term effects of ZINC13407541, 8n, and 13a on skeletal phenotypes in Hyp mice. (A) body length (n = 6–10). (B) body weight (n = 6–10). (C) tail length (n = 6–10). (D) femur length (n = 6). Data are expressed as the mean ± S.D. from serum samples of individual mice. *, **, and *** indicate statistically significant difference from vehicle control group. P values were determined by one-way ANOVA with Tukey’s multiple-comparisons test.

  • Fig. 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 8.

    Long-term effects of ZINC13407541, 8n, and 13a on bone mineral density and bone structure in Hyp mice. (A) BMD (n = 6–10). (B) Micro-CT 3D images, including width of the growth plate (GP, double red arrow, n = 6), femoral bone volume (BV/TV, n = 6), and cortical thickness (Ct.Th, n = 6). Data are expressed as the mean ± S.D. from serum samples of individual mice (n = 5). *, **, and *** indicate statistically significant difference from vehicle control group. P values were determined by one-way ANOVA with Tukey’s multiple-comparisons test.

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

    The weighted hydrogen-bond scores H (see eqs. 1 and 2 for details) in descending order for residues in the N-terminal domain of FGF23 that form hydrogen bonds with ZINC13407541, 13a, and 8n in the molecular docking

    ZINC1340754113a8n
    ResidueHResidueHResidueH
    Gln1560.417Tyr930.293Tyr930.159
    Asn1220.408Gln1560.278Gln1560.143
    Arg760.242Asn1220.207Thr860.096
    Ser770.159Thr860.120Tyr1540.091
    Tyr930.134Arg760.113Ser1370.074
    Thr860.115Ser770.101Gly1390.074
    Met740.083Met740.078Thr460.063
    Val840.083Val840.078Asn490.063
    Leu1460.027Ala450.035Ser770.063
    Ile750.024Gln670.031Arg760.061
    Gly380.012Leu1460.021Ser1550.052
    Glu780.009Asn490.015Ile750.047
    Ser1590.009Pro1520.015Leu1460.045
    Gln1180.007Tyr1540.015Met740.033
    Thr1190.007Ser1550.015Val840.033
    Ser340.024
    Gly380.024
    Pro1520.024
    Asn1620.024
    Ile1640.024
    Asp1250.020
    Tyr1270.020
    Ser1590.020
    • Ala, Alanine; Arg, Arginine; Asn, Asparagine; Asp, Aspartic acid; Glu, Glutamic acid; Gly, Glycine; Ile, Isoleucine; Leu, Leucine; Met, Methionine; Pro, Proline; Ser, Serine; Thr, Threonine; Tyr, Tyrosine; Val, Valine.

    • View popup
    TABLE 2

    Computationally estimated free energies of binding (ΔG) with standard errors for ZINC13407541, 13a, and 8n to Gln156 in the N-terminal domain of FGF23 using AutoDock VinaMPI and KDEEP

    The corresponding binding poses of ligands are shown in Fig. 2.

    CompoundΔG(VinaMPI) [kcal/mol]ΔG(KDEEP) [kcal/mol]
    ZINC13407541−7.0 ± 2.9−6.4 ± 0.3
    13a−7.3 ± 2.9−6.9 ± 0.5
    8n−5.8 ± 2.9−4.9 ± 0.6
    • View popup
    TABLE 3

    Serum biochemistry of Hyp mice treated with ZINC13407541 and its analogs

    Data are expressed as the mean ± S.D. from serum samples of individual mice (n = 5–8). *, **, and *** indicate statistically significant difference from vehicle control group. P values were determined by one-way ANOVA with Tukey’s multiple-comparisons test.

    ParametersVehicle
    (n = 7)
    ZINC13407541
    (n = 8)
    8n
    (n = 8)
    13a
    (n = 5)
    p-Value
    FGF23 (pg/ml)1413 ± 3662359 ± 861*1754 ± 4451378 ± 2890.0110
    Phosphate (mg/dl)4.6 ± 0.606.5 ± 1.02**6.7 ± 0.58**7.8 ± 1.08***<0.0001
    Calcium (mg/dl)8.0 ± 1.238.9 ± 1.228.4 ± 1.778.3 ± 1.630.7208
    PTH (pg/ml)78 ± 12122 ± 21**118 ± 20**138 ± 21***0.0002
    1,25(OH)2D (pg/ml)19 ± 1365 ± 14***69 ± 19***116 ± 14***<0.0001
    Aldosterone (pg/ml)278 ± 84389 ± 68*401 ± 113*497 ± 71***0.0031
    • View popup
    TABLE 4

    Gene-expression profiles in bone of Hyp mice treated with ZINC13407541 and its analogs

    Data are expressed as the fold changes relative to the housekeeping gene β-actin subsequently normalized to control mice (n = 5–7). *, **, and *** indicate statistically significant difference from vehicle control group. P values were determined by one-way ANOVA with Tukey’s multiple-comparisons test.

    GeneVehicle
    (n = 6)
    ZINC13407541
    (n = 6)
    8n
    (n = 7)
    13a
    (n = 5)
    p-Value
    Osteoblast lineage
     Fgfr11.00 ± 0.350.51 ± 0.20**0.56 ± 0.23**0.21 ± 0.07***0.0001
     Fgfr21.00 ± 0.120.98 ± 0.290.94 ± 0.320.44 ± 0.06**0.0010
     Fgfr31.00 ± 0.251.14 ± 0.241.16 ± 0.210.42 ± 0.17***<0.0001
     Fgfr41.00 ± 0.590.53 ± 0.25*0.45 ± 0.19**0.25 ± 0.06***0.0057
     Fgf11.00 ± 0.251.14 ± 0.401.01 ± 0.390.38 ± 0.15*0.0019
     Fgf21.00 ± 0.321.04 ± 0.311.01 ± 0.270.52 ± 0.16*0.0081
     Fgf231.00 ± 0.330.88 ± 0.180.93 ± 0.410.46 ± 0.15*0.0189
     Dmp11.00 ± 0.480.77 ± 0.180.88 ± 0.160.38 ± 0.16***0.0002
     Osteopontin1.00 ± 0.250.55 ± 0.11**0.56 ± 0.16**0.64 ± 0.12***<0.0001
     Bsp1.00 ± 0.340.87 ± 0.270.95 ± 0.290.90 ± 0.180.8607
     Mepe1.00 ± 0.161.68 ± 0.35*1.86 ± 0.44*5.42 ± 0.77***<0.0001
     Col11.00 ± 0.280.55 ± 0.16**0.62 ± 0.23*0.30 ± 0.10***<0.0001
     Alp1.00 ± 0.260.66 ± 0.20*0.60 ± 0.19**0.36 ± 0.08***0.0001
     Osteocalcin1.00 ± 0.271.06 ± 0.321.25 ± 0.393.36 ± 0.97***<0.0001
     Runx2-II1.00 ± 0.230.82 ± 0.410.91 ± 0.310.21 ± 0.11***0.0003
     Opg1.00 ± 0.201.02 ± 0.330.96 ± 0.290.92 ± 0.370.9488
     RankL1.00 ± 0.160.85 ± 0.180.97 ± 0.370.87 ± 0.110.6112
     Fzd21.00 ± 0.380.51 ± 0.21**0.62 ± 0.16*0.17 ± 0.08***<0.0001
     Wnt10b1.00 ± 0.270.53 ± 0.24**0.64 ± 0.16*0.12 ± 0.06***<0.0001
     Axin21.00 ± 0.250.57 ± 0.21**0.67 ± 0.17*0.11 ± 0.06***<0.0001
    Osteoclast
     Trap1.00 ± 0.170.91 ± 0.241.08 ± 0.270.86 ± 0.220.3383
     Mmp91.00 ± 0.210.81 ± 0.391.10 ± 0.341.11 ± 0.130.2358
    Chondrocyte
     Collagen II1.00 ± 0.453.72 ± 1.08*3.43 ± 2.27*14.4 ± 2.65***<0.0001
     VegfA1.00 ± 0.380.83 ± 0.510.77 ± 0.480.81 ± 0.270.7852
    Adipocyte
     PPARγ21.00 ± 0.320.43 ± 0.29**0.48 ± 0.31*0.10 ± 0.08***0.0001
     aP21.00 ± 0.130.78 ± 0.15*0.70 ± 0.16**0.23 ± 0.11***<0.0001
     Lpl1.00 ± 0.340.47 ± 0.23**0.54 ± 0.24*0.17 ± 0.07***<0.0001
    • aP2, adipocyte fatty acid-binding protein 2; Bsp, bone sialoprotein; Col1, type I collagen; Fzd2, frizzled class receptor 2; Lpl, lipoprotein lipase; Mmp9, matrix metallopeptidase 9; Opg, osteoprotegerin; PPARg2, peroxisome proliferator-activated receptor gamma 2; RankL, receptor activator of nuclear factor kappa B ligand; Runx2-II, type II runt-related transcription factor-2; Trap, tartrate-resistant acid phosphatase; VegfA, vascular endothelial growth factor A.

    • View popup
    TABLE 5

    Gene-expression profiles in kidney of Hyp mice treated with ZINC13407541 and its analogs (n = 5–6)

    Data are expressed as the fold changes relative to the housekeeping gene β-actin subsequently normalized to control mice. *, **, and *** indicate statistically significant difference from vehicle control group. P values were determined by one-way ANOVA with Tukey’s multiple-comparisons test.

    GeneVehicle
    (n = 6)
    ZINC13407541
    (n = 6)
    8n
    (n = 6)
    13a
    (n = 5)
    p-Value
    Fgfr11.00 ± 0.190.98 ± 0.150.95 ± 0.130.90 ± 0.290.8270
    Npt2a1.00 ± 0.101.36 ± 0.15*1.44 ± 0.19*1.76 ± 0.44***0.0007
    Npt2c1.00 ± 0.131.37 ± 0.15*1.41 ± 0.11**1.98 ± 0.48***<0.0001
    Klotho1.00 ± 0.121.32 ± 0.16*1.34 ± 0.16*1.66 ± 0.22***<0.0001
    Cyp24a11.00 ± 0.100.69 ± 0.15**0.64 ± 0.11***0.66 ± 0.16***0.0004
    Cyp27b11.00 ± 0.101.42 ± 0.14*1.48 ± 0.14*2.08 ± 0.61***0.0001
    NCC1.00 ± 0.150.64 ± 0.13***0.72 ± 0.17**0.55 ± 0.12***0.0002

Additional Files

  • Figures
  • Tables
  • Data Supplement

    • Supplemental Data -

      Figure S1. The computationally predicted interaction of ZINC13407541 and its two analogs, 13a and 8n, with the N terminal domain of FGF23 (PDB code: 5W21) Q156A mutant shown in (A) 3D structure; in (B) (C) and (D) 2D residue-contacting map for ZINC13407541, 13a, and 8n, respectively.

      Table S1. The raw results of hydrogen-bond analyses on binding poses of ZINC13407541 to the N-terminal domain of FGF23 in the molecular docking.

      Table S2. The raw results of hydrogen-bond analyses on binding poses of 13a to the N-terminal domain of FGF23 in the molecular docking.

      Table S3. The raw results of hydrogen-bond analyses on binding poses of 8n to the N-terminal domain of FGF23 in the molecular docking.

      Table S4. The conservation scores in descending order of the residues shown in Table 1 in the main text.

      Table S5. The computationally estimated free energies of binding (ΔG) with standard errors of ZINC13407541, 13a, and 8n to the N-terminal domain of FGF23 Q156A mutant using AutoDock VinaMPI and KDEEP.  

    • Supplemental PDB 1 -

      Supplemental Auxiliary Production PDB 1.  FGF23.pdb

    • Supplemental PDB 2 -

      Supplemental Auxiliary Production PDB 2.  PDB_5W21.pdb

    • Supplemental PDB 3 -

      Supplemental Auxiliary Production PDB 3.   ZINC13407541/ZINC13407541_Pose_1.pdb


    • Supplemental PDB 4 -

      Supplemental Auxiliary Production PDB 4.  ZINC13407541/ZINC13407541_Pose_2.pdb

    • Supplemental PDB 5 -

      Supplemental Auxiliary Production PDB 5.  ZINC13407541/ZINC13407541_Pose_3.pdb

    • Supplemental PDB 6 -

      Supplemental Auxiliary Production PDB 6.  ZINC13407541/ZINC13407541_Pose_4.pdb

    • Supplemental PDB 7 -

      Supplemental Auxiliary Production PDB 7.  ZINC13407541/ZINC13407541_Pose_5.pdb

    • Supplemental PDB 8 -

      Supplemental Auxiliary Production PDB 8.  ZINC13407541/ZINC13407541_Pose_6.pdb

    • Supplemental PDB 9 -

      Supplemental Auxiliary Production PDB 9.  ZINC13407541/ZINC13407541_Pose_7.pdb

    • Supplemental PDB 10 -

      Supplemental Auxiliary Production PDB 10.  ZINC13407541/ZINC13407541_Pose_8.pdb

    • Supplemental PDB 11 -

      Supplemental Auxiliary Production PDB 11. ZINC13407541/ZINC13407541_Pose_9.pdb

    • Supplemental PDB 12 -

      Supplemental Auxiliary Production PDB 12. ZINC13407541/ZINC13407541_Pose_10.pdb

    • Supplemental PDB 13 -

      Supplemental Auxiliary Production PDB 13.  ZINC13407541/ZINC13407541_Pose_11.pdb

    • Supplemental PDB 14 -

      Supplemental Auxiliary Production PDB 14. ZINC13407541/ZINC13407541_Pose_12.pdb

    • Supplemental PDB 15 -

      Supplemental Auxiliary Production PDB 15. ZINC13407541/ZINC13407541_Pose_13.pdb

    • Supplemental PDB 16 -

      Supplemental Auxiliary Production PDB 16. ZINC13407541/ZINC13407541_Pose_14.pdb

    • Supplemental PDB 17 -

      Supplemental Auxiliary Production PDB 17.  ZINC13407541/ZINC13407541_Pose_15.pdb

    • Supplemental PDB 18 -

      Supplemental Auxiliary Production PDB 18.  ZINC13407541/ZINC13407541_Pose_16.pdb

    • Supplemental PDB 19 -

      Supplemental Auxiliary Production PDB 19. ZINC13407541/ZINC13407541_Pose_17.pdb

    • Supplemental PDB 20 -

      Supplemental Auxiliary Production PDB 20. ZINC13407541/ZINC13407541_Pose_18.pdb

    • Supplemental PDB 21 -

      Supplemental Auxiliary Production PDB 21. ZINC13407541/ZINC13407541_Pose_19.pdb

    • Supplemental PDB 22 -

      Supplemental Auxiliary Production PDB 22. ZINC13407541/ZINC13407541_Pose_20.pdb

    • Supplemental PDB 23 -

      Supplemental Auxiliary Production PDB 23. 13a/13a_Pose_1.pdb

    • Supplemental PDB 24 -

      Supplemental Auxiliary Production PDB 24. 13a/13a_Pose_2.pdb

    • Supplemental PDB 25 -

      Supplemental Auxiliary Production PDB 25. 13a/13a_Pose_3.pdb

    • Supplemental PDB 26 -

      Supplemental Auxiliary Production PDB 26. 13a/13a_Pose_4.pdb

    • Supplemental PDB 27 -

      Supplemental Auxiliary Production PDB 27. 13a/13a_Pose_5.pdb

    • Supplemental PDB 28 -

      Supplemental Auxiliary Production PDB 28. 13a/13a_Pose_6.pdb

    • Supplemental PDB 29 -

      Supplemental Auxiliary Production PDB 29. 13a/13a_Pose_7.pdb

    • Supplemental PDB 30 -

      Supplemental Auxiliary Production PDB 30. 13a/13a_Pose_8.pdb

    • Supplemental PDB 31 -

      Supplemental Auxiliary Production PDB 31. 13a/13a_Pose_9.pdb

    • Supplemental PDB 32 -

      Supplemental Auxiliary Production PDB 32. 13a/13a_Pose_10.pdb

    • Supplemental PDB 33 -

      Supplemental Auxiliary Production PDB 33. 13a/13a_Pose_11.pdb

    • Supplemental PDB 34 -

      Supplemental Auxiliary Production PDB 34. 13a/13a_Pose_12.pdb

    • Supplemental PDB 35 -

      Supplemental Auxiliary Production PDB 35. 13a/13a_Pose_13.pdb

    • Supplemental PDB 36 -

      Supplemental Auxiliary Production PDB 36. 13a/13a_Pose_14.pdb

    • Supplemental PDB 37 -

      Supplemental Auxiliary Production PDB 37. 13a/13a_Pose_15.pdb

    • Supplemental PDB 38 -

      Supplemental Auxiliary Production PDB 38. 13a/13a_Pose_16.pdb

    • Supplemental PDB 39 -

      Supplemental Auxiliary Production PDB 39. 13a/13a_Pose_17.pdb

    • Supplemental PDB 40 -

      Supplemental Auxiliary Production PDB 40. 13a/13a_Pose_18.pdb

    • Supplemental PDB 41 -

      Supplemental Auxiliary Production PDB 41. 13a/13a_Pose_19.pdb

    • Supplemental PDB 42 -

      Supplemental Auxiliary Production PDB 42. 13a/13a_Pose_20.pdb

    • Supplemental PDB 43 -

      Supplemental Auxiliary Production PDB 43. 8n/8n_Pose_1.pdb

    • Supplemental PDB 44 -

      Supplemental Auxiliary Production PDB 44. 8n/8n_Pose_2.pdb

    • Supplemental PDB 45 -

      Supplemental Auxiliary Production PDB 45. 8n/8n_Pose_3.pdb

    • Supplemental PDB 46 -

      Supplemental Auxiliary Production PDB 46. 8n/8n_Pose_4.pdb

    • Supplemental PDB 47 -

      Supplemental Auxiliary Production PDB 47. 8n/8n_Pose_5.pdb

    • Supplemental PDB 48 -

      Supplemental Auxiliary Production PDB 48. 8n/8n_Pose_6.pdb

    • Supplemental PDB 49 -

      Supplemental Auxiliary Production PDB 49.  8n/8n_Pose_7.pdb

    • Supplemental PDB 50 -

      Supplemental Auxiliary Production PDB 50.  8n/8n_Pose_8.pdb

    • Supplemental PDB 51 -

      Supplemental Auxiliary Production PDB 51. 8n/8n_Pose_9.pdb

    • Supplemental PDB 52 -

      Supplemental Auxiliary Production PDB 52. 8n/8n_Pose_10.pdb

    • Supplemental PDB 53 -

      Supplemental Auxiliary Production PDB 53. 8n/8n_Pose_11.pdb

    • Supplemental PDB 54 -

      Supplemental Auxiliary Production PDB 54. 8n/8n_Pose_12.pdb

    • Supplemental PDB 55 -

      Supplemental Auxiliary Production PDB 55. 8n/8n_Pose_13.pdb

    • Supplemental PDB 56 -

      Supplemental Auxiliary Production PDB 56. 8n/8n_Pose_14.pdb

    • Supplemental PDB 57 -

      Supplemental Auxiliary Production PDB 57. 8n/8n_Pose_15.pdb

    • Supplemental PDB 58 -

      Supplemental Auxiliary Production PDB 58. 8n/8n_Pose_16.pdb

    • Supplemental PDB 59 -

      Supplemental Auxiliary Production PDB 59. 8n/8n_Pose_17.pdb

    • Supplemental PDB 60 -

      Supplemental Auxiliary Production PDB 60. 8n/8n_Pose_18.pdb

    • Supplemental PDB 61 -

      Supplemental Auxiliary Production PDB 61. 8n/8n_Pose_19.pdb

    • Supplemental PDB 62 -

      Supplemental Auxiliary Production PDB 62. 8n/8n_Pose_20.pdb

    • Supplemental PDB 63 -

      Supplemental Auxiliary Production PDB 63. Q156A/FGF23_Q156A.pdb

    • Supplemental PDB 64 -

      Supplemental Auxiliary Production PDB 64. Q156A/ZINC13407541_Pose_1.pdb

    • Supplemental PDB 65 -

      Supplemental Auxiliary Production PDB 65. Q156A/13a_Pose_1.pdb

    • Supplemental PDB 66 -

      Supplemental Auxiliary Production PDB 66. Q156A/8n_Pose_1.pdb

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 101 (6)
Molecular Pharmacology
Vol. 101, Issue 6
1 Jun 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Novel Small Molecule Fibroblast Growth Factor 23 Inhibitors Increase Serum Phosphate and Improve Skeletal Abnormalities in Hyp Mice
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Therapeutic Effects of FGF23 Antagonists in Hyp Mice

Zhousheng Xiao, Jiawang Liu, Shih-Hsien Liu, Loukas Petridis, Chun Cai, Li Cao, Guangwei Wang, Ai Lin Chin, Jacob W. Cleveland, Munachi O. Ikedionwu, Jesse D. Carrick, Jeremy C. Smith and Leigh Darryl Quarles
Molecular Pharmacology June 1, 2022, 101 (6) 408-421; DOI: https://doi.org/10.1124/molpharm.121.000471

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Therapeutic Effects of FGF23 Antagonists in Hyp Mice

Zhousheng Xiao, Jiawang Liu, Shih-Hsien Liu, Loukas Petridis, Chun Cai, Li Cao, Guangwei Wang, Ai Lin Chin, Jacob W. Cleveland, Munachi O. Ikedionwu, Jesse D. Carrick, Jeremy C. Smith and Leigh Darryl Quarles
Molecular Pharmacology June 1, 2022, 101 (6) 408-421; DOI: https://doi.org/10.1124/molpharm.121.000471
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • The binding site for KCI807 in the androgen receptor
  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics